Streetbeat News

Stock Prices

APP

BTIG has maintained its Buy rating for AppLovin (NASDAQ:APP) and increased its price target from $40.00 to $46.00. AppLovin's shares are currently trading up 1.44% over the last 24 hours, at $38.75 per share. A move to $46.00 would account for a 18.71% increase from the current share price.

Portfolio Pulse from Benzinga Insights

September 26, 2023 | 5:00 pm

PACB

Pacific Biosciences (NASDAQ:PACB) has received mixed ratings from analysts in the last quarter, with one bullish rating and four indifferent ratings. The average 12-month price target for the company has increased by 13.6% from the previous average of $12.50 to $14.2, according to five analysts.

Portfolio Pulse from Benzinga Insights

September 26, 2023 | 5:00 pm

MAA

Mizuho has maintained its Neutral rating for Mid-America Apartment (NYSE:MAA) but lowered its price target from $159.00 to $133.00. MAA's shares are currently trading down 0.6% at $129.70 per share. A move to $133.00 would represent a 2.54% increase from the current share price.

Portfolio Pulse from Benzinga Insights

September 26, 2023 | 5:00 pm

DIS

Walt Disney Company (NYSE:DIS) shares are trading lower as investors await the outcome of a vote on the tentative agreement between production studios and the Writers Guild of America. The ongoing writers' strike has led to a complete shutdown in production of new content and significant profit losses for Disney. The company's shares have declined by more than 8% over the last three months and are down over 18% over the last year.

Portfolio Pulse from Erica Kollmann

September 26, 2023 | 4:59 pm

IONS

Ionis Pharmaceuticals Inc has released topline results for the Phase 3 Balance study of olezarsen in people with familial chylomicronemia syndrome (FCS). The trial met its primary efficacy endpoint with a significant reduction in triglyceride levels. The drug also showed a 100% reduction in acute pancreatitis events compared to placebo. Ionis plans to file a New Drug Application in early 2024 with the FDA. Following the news, IONS shares are up 7.83%.

Portfolio Pulse from Vandana Singh

September 26, 2023 | 4:57 pm

IONS

Ionis Pharmaceuticals announced that the Phase 3 Balance study of olezarsen met the primary endpoint with a statistically significant reduction in triglyceride levels versus placebo. This news has led to a rise in the company's share prices.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 4:57 pm

SLNO

SNX

Several stocks experienced significant movement in Tuesday's mid-day session. Soleno Therapeutics, Femasys, Intercept Pharmaceuticals, Immunovant, Tharimmune, Acasti Pharma, Cano Health, Bullfrog AI Holdings, Avalo Therapeutics, Adaptive Biotechnologies, Infobird, ARS Pharmaceuticals, Roivant Sciences, Verve Therapeutics, Pliant Therapeutics, Fisker, Planet Green Holdings, BYND Cannasoft Enterprises, Acutus Medical, Aclarion, Vera Therapeutics, Blue Star Foods, NightHawk Biosciences, and Precigen saw gains. Meanwhile, TransCode Therapeutics, Murphy Canyon Acquisition, Davis Commodities, Molekule Group, Polished.com, United Natural Foods, MicroAlgo, Genetron Holdings, Greenfire Resources, Novo Integrated Sciences, Ebix, New Pacific Metals, Biophytis, Roadzen, Akili, FaZe Holdings, MSP Recovery, TROOPS, Sacks Parente Golf, and TD SYNNEX experienced losses.

Portfolio Pulse from Lisa Levin

September 26, 2023 | 4:56 pm

DMK

DMK Pharmaceuticals' stock was halted on a circuit breaker due to a sharp downside movement. However, the stock is now up by 162.6%.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 4:53 pm

FERG

Ferguson PLC (NYSE:FERG) reported a Q4 FY23 sales decline of 1.7% YoY to $7.8 billion, beating the consensus of $7.6 billion. Adjusted EPS was $2.77, above the consensus of $2.46. The company declared a quarterly dividend of $0.75, a 9% increase compared to a quarter of the prior year's total dividend. For FY24, Ferguson expects net sales to be broadly flat YoY and an adjusted operating margin between 9.2%-9.8%. The company's shares are trading higher by 4.29%.

Portfolio Pulse from Nabaparna Bhattacharya

September 26, 2023 | 4:50 pm

CADL

Candel Therapeutics Inc (NASDAQ:CADL) has revealed updated activity data from its ongoing phase 2 trial of CAN-2409 plus valacyclovir in combination with continued immune checkpoint inhibitor treatment in patients with non-resectable, stage III/IV non-small cell lung cancer. Of the 40 evaluable patients, 15 have lived ≥ 12 months; of these, 10 patients have lived > 18 months. Candel expects to share topline overall survival data for Cohort 2 in the second quarter of 2024. CADL shares are down 18.24% at $0.92 on the last check Tuesday.

Portfolio Pulse from Vandana Singh

September 26, 2023 | 4:46 pm